Literature DB >> 30522968

Drug development for glioma: are we repeating the same mistakes?

Roger Stupp1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30522968     DOI： 10.1016/S1470-2045(18)30827-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

1.  An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas.

Authors:  Jingtao Wang; Xuejun Zheng; Jinling Zhang; Hao Xue; Lijie Wang; Rui Jing; Shuo Chen; Fengyuan Che; Xueyuan Heng; Gang Li; Fuzhong Xue
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

2.  Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Authors:  Pia S Zeiner; Martina Kinzig; Iris Divé; Gabriele D Maurer; Katharina Filipski; Patrick N Harter; Christian Senft; Oliver Bähr; Elke Hattingen; Joachim P Steinbach; Fritz Sörgel; Martin Voss; Eike Steidl; Michael W Ronellenfitsch
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

Review 3.  Research progress of anti-glioma chemotherapeutic drugs (Review).

Authors:  Yi-Shu Zhou; Wei Wang; Na Chen; Li-Cui Wang; Jin-Bai Huang
Journal:  Oncol Rep       Date:  2022-04-01       Impact factor: 3.906

Review 4.  Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.

Authors:  Wenda Huang; Zhaonian Hao; Feng Mao; Dongsheng Guo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

5.  Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial.

Authors:  Ivo W Tremont-Lukats; Bin S Teh
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.